Inotek Pharmaceuticals is a privately held biotechnology company based in Lexington, MA, focused on the discovery and development of innovative drugs to address serious eye diseases such as glaucoma, ocular hypertension, age-related macular degeneration, and retinal neuropathies. Their lead program, trabodenoson INO-8875, is a highly selective adenosine mimetic that targets the A1 sub-receptor, offering a novel mechanism of action for the treatment of elevated intraocular pressure associated with glaucoma and ocular hypertension.
With a deep pipeline of drug candidates, Inotek Pharmaceuticals aims to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for eye disease treatments. Their experienced management team and successful track record in advancing clinical programs towards commercialization make them a promising player in the field of ocular drug development.
Generated from the website